Country for PR: United States
Contributor: PR Newswire New York
Tuesday, July 14 2020 - 20:00
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia
SAN DIEGO and SAFFRON WALDEN, United Kingdom, July 14, 2020 /PRNewswire-AsiaNet/ --

Invivoscribe, Inc., an industry pioneer and global leader in the field of 
precision diagnostics announces the launch of a fully integrated drug 
development engine. This new engine will combine with its in-house expertise in 
diagnostics development and worldwide access to patients and clinical testing 
capabilities to accelerate drug development. 

Logo - 

Invivoscribe's therapeutics division also announced today that the company has 
in-licensed technology involving a preclinical molecule and associated small 
molecules from Domainex Ltd. Domainex is a rapidly growing, well established 
integrated drug discovery service company in the UK that has utilized its 
novel, proprietary technologies to develop a first-in-class small molecule 
program against a difficult to target enzyme. Under the license agreement, 
Invivoscribe will develop and commercialize certain molecules generated by 
Domainex as oral immunotherapy agents to treat hematological malignancies, 
including acute myeloid leukemia. The overall financial aspects of the deal 
include an upfront payment and subsequent milestone payments based on various 
phases of drug development, regulatory submission and commercialization, 
including royalties on the resulting commercial products. 

"The launch of Invivoscribe Therapeutics was an obvious next step for 
Invivoscribe. We have assembled an extraordinary team of drug development 
experts with decades of experience leading discovery, preclinical development, 
and directing pharmaceutical sciences. They are well versed in taking small 
molecules through all phases of candidate selection into human trials. They've 
joined our diagnostics, bioinformatics, and regulatory teams that have years of 
experience using our tests to assist pharma companies in getting their drugs 
approved worldwide, and our international network of LabPMM clinical 
laboratories with ready access to oncology patients. All of our interactions 
with Domainex have been extremely positive and we are impressed with the 
molecules they have discovered," said Jeffrey Miller, CSO & CEO of Invivoscribe.

Dr. Tom Mander, CEO of Domainex, added, "This license agreement reflects the 
extensive capabilities of Domainex to generate molecules with therapeutic 
potential. We are delighted that Invivoscribe has decided to invest in moving 
the program through drug development ultimately to approval and 
commercialization. This deal is in keeping with our strategy to grow rapidly 
our drug discovery service business to enrich the pipelines of our partners. I 
want to thank all of our scientists who have worked on the program and 
acknowledge the support we have received along the way. I wish Jeff and his 
team every success with the program and the launch of their new division."

About Invivoscribe

Invivoscribe has been Improving Lives with Precision Diagnostics® for more than 
twenty-five years, advancing the field of precision medicine by developing and 
selling standardized reagents, tests, and bioinformatics tools to more than 700 
customers in 160 countries. Invivoscribe also has a significant impact on 
global health working with pharmaceutical companies to accelerate approvals of 
new drugs and treatments by supporting international clinical trials, 
developing, commercializing companion diagnostics, and providing expertise in 
both regulatory and laboratory services. With its proven ability to provide 
global access to distributable reagents, kits, and controls, as well as 
clinical trial services through our international clinical lab subsidiaries 
(LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional 
information please contact Invivoscribe at: or 

About Domainex:

Domainex is a leading, award-winning integrated medicines research service 
partner working with ambitious life science organisations from around the 
globe. We have been setting new standards in research since 2001, working 
collaboratively with pharmaceutical and biotechnology companies, patient 
foundations and leading academic institutions. 

We provide innovative and customised biology and chemistry services to advance 
the disease research projects of our partners, from target expression to 
pre-clinical development candidate nomination. Working with Domainex maximises 
the chance of successful progression for our partners' research and our 
approach consistently saves up to 30% of the time needed to discover new 
medicines by comparison with the industry average. Our innovative science and 
extensive technical capabilities enable us to produce novel medicines to treat 
diseases with strong commercial potential. We work closely and collaboratively 
with our clients to understand their aspirations, bringing our ideas, know-how 
and wealth of experience to bear on their projects.

Our highly qualified and experienced team of dedicated research scientists has 
an unrivalled breadth of knowledge, access to a wide range of technologies and 
a proven track record of successful innovation in solving research challenges 
including being named on over 60 patent applications and the invention of 
numerous candidate drugs. We aim to deliver successful outcomes efficiently and 
quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and our award-winning services can be found at

SOURCE: Invivoscribe, Inc.

CONTACT: Domainex, Dr Tom Mander, E:, or Media 
Relations, Sciad Communications, Deborah Cockerill / Juliette Craggs / Victoria 
Deaner, T: +44(0)20 3405 7892, E: